In the high-stakes world of Indian healthcare, where private equity (PE) firms have funneled over $15.5 billion into hospital chains and diagnostic networks over the past five years, the narrative has become somewhat predictable: institutional capital buys in, mandates aggressive expansion through M&A, and plans a multi-year exit strategy. However, in October 2025, a 40-year-old institution from Coimbatore, The Eye Foundation, challenged this industry orthodoxy.
When the eye-care chain decided to raise its first round of external equity, it bypassed the usual suspects—Temasek, Blackstone, TPG, and KKR—that dominate the sector. Instead, it courted Verlinvest, a global venture capital firm known for building consumer brands like Epigamia, Wakefit, and the beauty platform Purplle. The deal, which saw Verlinvest inject Rs 650 crore for a 20% stake, marks a strategic divergence that signals a shift in how specialized healthcare providers view their own business models.
The Strategic Departure from Traditional Healthcare Funding
For decades, the Indian hospital sector has been a magnet for healthcare-focused private equity. With roughly 60% of the $15.5 billion in recent investments flowing directly into hospital infrastructure, the landscape has become crowded with investors who share a similar playbook: scaling up bed counts and consolidating smaller chains to achieve economies of scale.
The Eye Foundation’s founder and CEO, D. Ramamurthy, viewed this landscape with a degree of skepticism. Despite having a robust balance sheet that attracted a flurry of "suitors," Ramamurthy was wary of the "fly-by-night" nature of traditional PE exits. "It is an unusual choice for the sector," Ramamurthy acknowledged in a recent discussion. "But we did not want someone with a definite, short-term timeline who wants to exit in five years."
By opting for a consumer-focused fund, The Eye Foundation is positioning itself not merely as a clinical service provider, but as a brand-led retail health entity. This distinction is critical; it suggests that the company views patient experience, brand equity, and long-term loyalty—hallmarks of the FMCG and retail sectors—as the primary drivers of its future growth, rather than the traditional hospital metrics of bed-occupancy rates and acquisition-heavy expansion.
Chronology of Growth: A Trajectory of Consistent Performance
The Eye Foundation’s decision to partner with Verlinvest was not born out of financial desperation, but from a position of strength. Over the last several years, the company has maintained a trajectory of growth that has caught the attention of both investors and analysts.
- FY24: The company recorded a revenue of Rs 278 crore, establishing a foundation of steady, organic growth.
- FY25: Revenue climbed to Rs 330 crore, reflecting the company’s increasing penetration into key markets.
- FY26: The momentum continued as the topline touched Rs 409 crore.
- FY27 (Projected): Ramamurthy asserts that the firm is on track for a 35% year-on-year jump, with revenue expected to touch Rs 550 crore.
Beyond the topline growth, the firm’s EBITDA margins have consistently hovered around 35%. In an industry currently grappling with intense regulatory scrutiny and margin compression, this figure is an outlier. For context, industry peers like Dr. Agarwal’s Eye Hospital and ASG Eye Hospital have reported margins in the 22% to 29% range.
Supporting Data: The Cost of Acquisition vs. Organic Growth
The contrast between The Eye Foundation and its peers becomes most apparent when examining how they utilize capital.
The industry standard for large chains, such as Dr. Agarwal’s—backed by heavyweight investors like TPG and Temasek—has been an aggressive, acquisition-led growth model. Between 2022 and 2023, these investors poured a combined Rs 1,690 crore into the firm. Much of this capital was funneled into acquiring smaller chains to rapidly increase the company’s geographic footprint.
Data indicates that in the three years leading up to FY26, Dr. Agarwal’s spent approximately Rs 1,215 crore on acquisitions. Interestingly, this aggressive spend occurred despite the company generating only about Rs 315 crore in free cash flow. This reliance on external capital to fund acquisitions creates a high-pressure environment where the firm must constantly perform to satisfy the "exit-first" mindset of its PE backers.
In contrast, The Eye Foundation’s valuation—which Ramamurthy notes is on par with ASG Eye Hospital and exceeds the implied valuation of recent Dr. Agarwal’s fundraises—suggests that investors are willing to pay a premium for consistent, organic-led growth. By prioritizing profitability and brand-driven patient retention, The Eye Foundation is effectively "de-risking" its operations, making it a more attractive long-term asset for a patient investor like Verlinvest.
The "Retailization" of Healthcare: Implications for the Sector
The choice of an FMCG-focused investor carries profound implications for the future of healthcare in India. Historically, healthcare providers have focused on clinical outcomes and medical technology. However, as the industry matures, the "retailization" of healthcare is becoming a dominant trend.
1. Patient as a Consumer
By working with a firm that understands consumer behavior, The Eye Foundation is likely focusing on the "patient journey." In a competitive market where medical services are increasingly commoditized, the ability to provide a premium, seamless, and brand-consistent experience becomes a primary differentiator.
2. Efficiency as a Competitive Moat
The 35% EBITDA margin reported by The Eye Foundation is a testament to operational excellence. While healthcare analysts initially expressed surprise at these figures given the current regulatory climate, they highlight that the company has likely optimized its supply chain, doctor-to-patient ratios, and administrative overheads in a way that mimics efficient retail operations.
3. Independence from the M&A Treadmill
The most significant implication is the shift away from the "growth at all costs" model. By resisting the urge to participate in the M&A arms race, The Eye Foundation is preserving its internal culture and operational integrity. This allows the leadership team to focus on long-term sustainability rather than the immediate pressures of integrating new acquisitions every fiscal year.
Challenges and Future Outlook
While the strategy has proven successful thus far, it is not without its risks. The eye-care sector in India is becoming increasingly fragmented yet competitive. Large chains are aggressively entering tier-2 and tier-3 cities, and the regulatory environment regarding pricing and medical standards remains volatile.
Furthermore, by taking a 20% stake, Verlinvest has placed a significant bet on the longevity of this specific business model. If the retail-led growth strategy hits a ceiling, the pressure to pivot toward more traditional, volume-driven growth may return.
However, for now, the partnership between a 40-year-old eye-care chain and a consumer-goods-focused VC fund stands as a beacon of institutional confidence in a different kind of healthcare business. It suggests that for companies with strong fundamentals, the path to scale does not always have to be paved by the traditional giants of the private equity world.
As the industry watches, the success of The Eye Foundation may well trigger a trend, encouraging other mid-sized hospital chains to look beyond the standard "healthcare-only" investor pool. In doing so, they might find that the best partners for their future are not those who know the hospital business best, but those who know the customer best.
The Eye Foundation has made its move. By prioritizing patient-brand loyalty and disciplined growth over the rapid, debt-fueled acquisition cycles of its peers, it is betting that the most valuable hospitals of the future will be the ones that function less like clinical institutions and more like trusted, consumer-facing brands. Whether this model can scale nationally without losing its unique, high-margin efficiency remains the defining question for the years ahead.
